-+ 0.00%
-+ 0.00%
-+ 0.00%

ResMed Presents Plan for Annual Gross Margin Gains Through 2030

PUBT·11/20/2026 00:53:25
Listen to the news
ResMed Presents Plan for Annual Gross Margin Gains Through 2030
  • ResMed reported Q1 FY27 core constant-currency revenue growth of 7% in its company overview presentation.
  • Non-GAAP earnings per share rose 14%; non-GAAP operating margin reached 35.8%.
  • Trailing 12-month revenue totaled $5.7 billion; free cash flow was $1.6 billion.
  • Gross margin exceeded expectations, benefiting from the timing of supply-chain expansion investments.
  • The operational improvement pipeline targets annual gross margin gains of double-digit basis points through 2030.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.